[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:gastroenteropancreatic-neuroendocrine-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":42,"states":43},"Gastroenteropancreatic Neuroendocrine Carcinoma",5,4,[8,16,23,29,35],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07006727","Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.218817Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05652686","A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)",[20],"Phase 1\u002FPhase 2","2026-08-26T02:16:14.341106Z","2026-07-19T19:36:05.121911Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07080242","Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors",[12],"2026-08-26T02:15:59.318403Z","2026-07-05T05:32:16.735201Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07488923","A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R\u002FR SCLC or Select NECs (SPECTRAL-1)",[12],"2026-08-26T02:16:54.876240Z","2026-05-13T02:55:06.710634Z",{"nct_id":36,"title":37,"phases":38,"status":39,"updated_at":40,"content_modified":41},"NCT02270567","RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide",[],"ENROLLING_BY_INVITATION","2026-08-26T02:17:05.997056Z","2026-06-16T05:54:07.950523Z",[],[44,48,51],{"state":45,"count":46,"slug":47},"Connecticut",3,"connecticut",{"state":49,"count":46,"slug":50},"Texas","texas",{"state":52,"count":46,"slug":53},"Washington","washington"]